Incyte Says Phase 3 TRuE-V Trial Met Primary And Key Secondary Endpoints
WASHINGTON (dpa-AFX) - Incyte Corp. (INCY) announced Monday positive topline results from its pivotal Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream, an investigational, nonsteroidal, anti-inflammatory, JAK inhibitor, topical therapy, in adolescent and adult patients (age ?12 years) with vitiligo.
Both the TRuE-V1 and TRuE-V2 studies met the primary endpoint, demonstrating that significantly more patients treated with ruxolitinib cream 1.5% twice daily (BID) achieved a ?75% improvement from baseline in the facial vitiligo area scoring index (F-VASI75) compared to patients treated with a vehicle control at Week 24.